|
Allergan Finance LLC 8-K 2009 Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
July 1, 2009 WATSON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Registrants telephone number, including area code: (951) 493-5300
(Former name or former address, if changed since last report): Not applicable.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
TABLE OF CONTENTS
Table of Contents
On July 1, 2009, Watson Pharmaceuticals, Inc. (Watson) entered into Amendment No. 1 (the
Amendment) to the Credit Agreement, dated as of November 3, 2006, by and among Watson, Canadian
Imperial Bank of Commerce, acting through its New York agency, as administrative agent, Wachovia
Capital Markets, LLC, as syndication agent, a syndicate of lenders, and Wells Fargo Bank, National
Association, Union Bank of California, N.A., Sumitomo Mitsui Banking Corporation, as documentation
agents and the financial institutions from time to time party thereto (the Credit Agreement).
The Amendment provides for, among other things, the following:
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|